A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Trial Profile

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Orient Europharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2016 Planned End Date changed from 1 Sep 2018 to 1 Mar 2018.
    • 13 Nov 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top